BioPorto Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tony Pare

Algemeen directeur

DKK 6.3m

Totale compensatie

Percentage CEO-salaris	55.7%
Dienstverband CEO	1.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	6.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tony Pare's beloning veranderd ten opzichte van BioPorto's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-DKK 75m
Dec 31 2022	DKK 6m	DKK 4m	-DKK 76m
Sep 30 2022	n/a	n/a	-DKK 68m
Jun 30 2022	n/a	n/a	-DKK 62m
Mar 31 2022	n/a	n/a	-DKK 59m
Dec 31 2021	DKK 8m	DKK 374k	-DKK 57m

Compensatie versus markt: De totale vergoeding ($USD 913.34K ) Tony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 356.13K ).

Compensatie versus inkomsten: De vergoeding van Tony is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Tony Pare (59 yo)

1.5yrs

Tenure

DKK 6,340,000

Compensatie

Mr. Anthony Paul Pare, also known as Tony, serves as Chief Executive Officer of BioPorto A/S since November 2021. He served as Chief Commercial Officer at T2 Biosystems, Inc. since January 08, 2020. He ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Pare	Chief Executive Officer	1.5yrs	DKK 6.34m	geen gegevens
Neil Goldman	Executive VP & CFO	1.5yrs	DKK 5.23m	geen gegevens
Lars Uttenthal	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Gry Larsen	General Counsel	no data	geen gegevens	geen gegevens
Jennifer Zonderman	VP of Global Marketing & US Commercialization	4yrs	geen gegevens	geen gegevens
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	less than a year	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van BIOPOC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Donnie Hardison	Independent Vice Chairman of the Board	2.1yrs	DKK 715.00k	geen gegevens
John McDonough	Independent Chairman of the Board	2.1yrs	DKK 835.00k	geen gegevens
Claudio Ronco	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Ninfa Saunders	Director	less than a year	geen gegevens	geen gegevens
Michael Singer	Independent Director	3.8yrs	DKK 715.00k	0.062% DKK 328.6k
Peter Eriksen	Director	1.5yrs	DKK 292.00k	0.039% DKK 207.0k
Jan Christensen	Independent Director	2.1yrs	DKK 275.00k	geen gegevens
Andrew Lewington	Vice Chairman of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Laurent Jacob	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Michael Haase	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Hilde Geus	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens

6.5yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOPOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).

BioPorto Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Recent updates

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

Bioporto A/S Affirms Earnings Guidance for 2024

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report First Half, 2024 Results on Aug 01, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

BioPorto A/S Maintains Earnings Guidance for the Year 2023

BioPorto A/S Maintains Financial Guidance for 2023

Less than half of directors are independent

BioPorto A/S, Annual General Meeting, Apr 27, 2023

Less than half of directors are independent

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd